Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Tom Waddell(Royal Marsden NHS Foundation Trust), Ian Chau(Royal Marsden NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), David González de Castro(Royal Marsden NHS Foundation Trust), Alicia Okines(Royal Marsden NHS Foundation Trust), Andrew Wotherspoon(Royal Marsden NHS Foundation Trust), Claire Saffery(Royal Marsden NHS Foundation Trust), Gary Middleton(Royal Surrey County Hospital), Jonathan Wadsley(Weston Park Cancer Centre), David Ferry(Russells Hall Hospital), Wasat Mansoor(The Christie NHS Foundation Trust), Tom Crosby(Velindre Cancer Centre), Fareeda Y. Coxon, David A. Smith(Clatterbridge Cancer Centre NHS Foundation Trust), Justin S. Waters(Maidstone Hospital), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Stephen Falk(At Bristol), Sarah Slater(Barts Health NHS Trust), Clare Peckitt(Royal Marsden NHS Foundation Trust), Yolanda Barbáchano(Royal Marsden NHS Foundation Trust)
Cited by 728
Abstract
Related Papers
No related papers found
Powered by citation graph analysis